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INTRODUCTION
The diagnosis of Invasive Lobular Carcinoma (ILC)
in the relapse setting is as problematic and challenging
as in the primary setting due to the enigmatic nature of
this malignant process.
As discussed in previous chapters for early ILC, this
special neoplastic process is often difficult to identify
by clinical and imaging studies, which applies to the
metastatic situation, too. These difficulties relate to a
variety of factors, including the diffusely infiltrative na-
ture of the malignant process, the spatial and site spe-
cific pattern of metastatic disease which is associated
with ILC.
It is of the utmost importance that the past history of
Invasive Lobular Carcinoma of breast is available to the
entire clinical team involved in the management of the
individual patient, even if this history is many (often 20
or 30) years prior to the current clinical episode.
Invasive Breast Carcinoma of any histological type
may be associated with relapse which may be loco
regional, involving the breast, chest wall or regional
lymph nodes, or distant relapse at any anatomical site.
Due to the possibility of relapse and the increased
risk of a second primary breast carcinoma, it is recom-
mended that all individuals should be followed up. Fol-
low up should include clinical and radiological options
for assessment of the patient as a whole as well as both
the treated and contra lateral breast.
The aim of the follow up is that the early detection of
recurrence either local or distant will be more effective
and be associated with a survival benefit however no
robust evidence exists to support this belief. Through
regular surveillance the clinician aims to identify recur-
rence or be informed of new symptoms affecting the
patient at the earliest opportunity.
It is known that Invasive Lobular Carcinoma has an
early advantage in disease free survival when compared
to Invasive Ductal Carcinoma, but when compared at
6 & 10 years the invasive ductal carcinoma group has
a late advantage. Invasive Lobular Carcinoma is asso-
ciated with an increased incidence of bone metastases
but a decrease in regional and lung relapses [1].
Thus, due to the nature of this process, the diagnosis
of cancer relapse can be difficult.
FOLLOW UP OF INVASIVE BREAST CANCER
All individuals with the diagnosis of invasive breast
carcinoma should be offered regular follow up for some
time after the diagnosis of their primary disease. Fol-
low up is advised to allow identification of recurrent
disease which may be local or systemic, the supervision
of adjuvant treatment & side effects. Follow up also
permits the review of individuals involved in clinical
trials. Careful follow up with accurate data collection
is essential for the success of all clinical trials which
are dependent on accurate information on individual
patient outcome to assess the efficacy of the trial.
The American society of Clinical Oncology (ASCO)
recommends that Breast Cancer survivors be followed
up by regular history, physical examination and mam-
mography. Examination should be performed at 3–
6 months for the first 3 years 6–12 months for years 4–5
& annually thereafter. If the individual has had con-
servation surgery a post treatment mammogram should
be obtained 1 year after the initial mammogram and at
least 6 months after completion of radiotherapy. There-
after a yearly mammographic examination should be
performed unless otherwise indicated. Those at high
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risk of familial breast cancer should be referred for
genetic counselling [2].
ASCO guidelines do not recommend follow up with
CBC, chemistry pane, bone scan, chest x-ray, CT scan,
PET scan MRI or tumour markers in the otherwise
asymptomatic patient with no specific clinical findings.
In the United Kingdom the National Institute for
Clinical Excellence (N.I.C.E.) advises that all cases of
invasive breast cancer should be followed up for these
reasons. The exact schedule and length of time of
follow varies from unit to unit. Visit schedules vary
from 3, 6 or 12 months and the length of follow up
varies from 2–10 years [3].
Follow up involves clinical examination and mam-
mography in the first instance. Between one half and
one third of local recurrence is detected by mammog-
raphy alone. Mammography is not an effective method
of detecting skin or chest wall recurrence. This is usu-
ally detected clinically or skin changes are noted by the
patient. Breast ultrasound is not recommended as a fol-
low up tool but it may be a useful adjunct in the dense
breast or when the initial tumour is mammographically
occult as is often the issue with Invasive Lobular Car-
cinoma. Magnetic Resonance Imaging is not currently
recommended for routine surveillance but can be used
for the further assessment of problem areas.
If at the clinic visit either local or systemic recurrence
is suspected due to clinical findings or symptoms other
imaging investigations may be appropriate [3].
LOCAL RELAPSE
As with all invasive breast carcinoma, Invasive Lob-
ular Carcinoma is associated with a risk of local re-
currence of 0.5–1% per annum. This risk is life long
and includes new primary carcinoma in the ipsilateral
breast. As highlighted in previous chapters Invasive
Lobular Carcinoma is more often occult on imaging
than other types of invasive breast carcinomas. This
issue remains problematic in the relapse setting. This
may be the result of Invasive Lobular Carcinoma be-
ing associated with the main glandular density of the
breast [4] or due to the failure of the tumour cells to
elicit a desmoplastic response resulting in false negative
imaging [1].
The use of ultrasound and Magnetic Resonance
Imaging as adjuncts to mammography improves the
sensitivity of detection of Invasive Lobular Carcino-
ma. In the primary diagnostic setting a study involving
28 biopsy proven cases of invasive lobular carcinoma
showed mammographic sensitivity of 79%, ultrasound
sensitivity of 68% and MRI sensitivity of 83% in the
detection of invasive lobular carcinoma [5]. It is likely
that similar numbers would be achieved in the local re-
lapse setting. Magnetic resonance imaging has increas-
ingly become accepted as a management tool in breast
disease. It has the greatest sensitivity of all imaging
modalities but is hampered by its low specificity [6].
When dealing with Invasive Lobular Carcinoma MRI
has the highest cancer detection rate when compared to
other imaging modalities.
While MRI is superior in detection of ILC it is es-
sential that all MRI detected suspicious lesions are con-
firmed histologically [7].
Local nodal recurrence is usually detected clinically
either in the axilla or supraclavicular area but may also
be detected by CT staging.
Thus detection of local recurrence is dependent on
clinical examination and imaging. In general, all sus-
pected local recurrence should be confirmed histologi-
cally.
DISTANT RELAPSE
The specific histological subgroups of invasive lobu-
lar carcinoma, discussed in this monograph in the chap-
ter on histology, are associated with different patterns
of prognosis with classical lobular carcinoma having a
better outlook than the variant forms, the variant sub-
sets showing more frequent recurrence and death from
disease [8]. A study of 530 cases of invasive lobular
carcinoma found that 57% of cases were of classical
type, 19% alveolar, 11% solid and 13% pleomorphic
subtype. The non classical types of ILC were associ-
ated with a higher risk of breast related events and a
trend towards reduced disease free survival [9].
As detailed in the chapter on prognosis of this mono-
graph, Invasive Lobular Carcinoma is associated with
an increased incidence of bone events but a decreased
incidence of regional and lung events when compared
to invasive ductal carcinoma [1].
Another clinicopathological analysis of 975 cases
of invasive lobular carcinoma studied 726 cases of
pure invasive lobular carcinoma & 249 cases of mixed
ductal/lobular carcinoma showed that bone involve-
ment was more common in ILC and that metastatic
spread to peritoneum, uterus, ovary, gastrointestinal
tract and skin was more common in ILC compared to
non ILC [10].
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Contrast enhanced CT is the state of the art modality
for restaging of oncological patients. A CT study of
56 patients with metastatic lobular carcinoma identified
metastatic disease in common sites e.g. lymph node,
lung and liver but also in peritoneum, colon, pleura,
adnexa, stomach, retroperitoneum and small bowel. In
this study 32% of patients had gastrointestinal tract
involvement manifest as bowel thickening on CT scan
& 11% of patients had hydronephrosis [11].
Carcinomatous meningitis is rare in breast carcino-
ma and it is usually associated with highly aggressive
disease behaviour. Carcinomatous meningitis is said
to occur in 1–3.5% of cases of metastatic breast carci-
noma. In cases with brain metastases 6% display lep-
tomeningeal involvement. The individual can present
with cerebral, cranial nerve and spinal signs and symp-
toms or a mononeuritis multiplex presentation. The
diagnosis may be made on CT scanning or with MRI
as a useful aid to diagnosis.CSF examination confirms
the diagnosis. In a study of 35 cases of leptomenigeal
disease were identified. This affected 0.86% of all
cases in the study population and 1.9% of those with
recurrent disease 67% of these cases were of lobular
or mixed histological subtype. 14% of the cases had
no other metastatic disease at presentation. This is a
highly aggressive form of relapse with median interval
from primary treatment to relapse of 10.9 months and
from recurrence to death of 15 months [12].
Bone marrow metastases are also observed in Inva-
sive Lobular Carcinoma. In a study of 54 patients with
ILC marrow involvement was suspected. The study
concluded that examination of bone marrow specimens,
in cases of known ILC, should utilise cytokeratin im-
munohistochemistry to ensure maximum detection of
clinically relevant metastases [13].
The pattern of relapse in ILC can be confusing to the
clinician. Metastases may present more than 30 years
after the primary diagnosis. Local recurrence is always
a possibility many years after primary diagnosis. A
presenting symptom of haeamatemesis, dysphagia or
haemoptysis may be due to recurrent lobular carcinoma
initially diagnosed many years ago. Recurrent lobular
carcinoma may present as an orbital or periadnexal
swelling related to the eye, as described in several case
reports.
A post-mortem study from 1991, examined 226 cas-
es of metastatic breast carcinoma including 25 cases
of invasive lobular carcinoma. The authors concluded
that lobular subtype was more often associated with
metastases to the peritoneum/retroperitoneum, hollow
viscera, internal genital organs, leptomeninges and my-
ocardium [14].
HISTOLOGICAL CONFIRMATION
In many cases of systemic relapse biopsy confirma-
tion is not possible and imaging modalities are relied
upon before instigating treatment.
If biopsy is possible, at any site or with any present-
ing symptom the reporting pathologist should be given
the information that the patient has a history of inva-
sive lobular carcinoma. This will prevent unnecessary
diagnosis of second malignancies, in particular gastric
carcinoma, which has morphological similarities to in-
vasive lobular carcinoma on H and E examination.
If the morphology of the cancer infiltration is sus-
picious of an invasive lobular carcinoma, further im-
munohistochemistry for E-Cadherin, cytokeratin and
hormone receptors can be carried out.
Comparing the morphology of the recurrent carci-
noma with the primary tumor if available, can confirm
the morphological similarity. If the recurrent tumour
can be biopsied, this is advisable as it allows repeat-
ed assessment of the biomarker status. Several studies
have shown variation in biomarker status between the
original tumour and metastatic disease which may alter
treatment strategy [15].
The morphological and immunohistochemical fea-
ture of invasive lobular carcinoma have been discussed
in previous chapters. In the following chapter three
case illustrations of distant/late relapses of ILC are pre-
sented.
There are also situations where carcinomas arising
in other sites may show morphological similarities to
Invasive Lobular Carcinoma. On rare occasions these
tumours may metastasise to the breast and be mistaken
for a primary breast carcinoma with lobular features.
This error can be prevented if the presence of another
primary carcinoma is known. On the other hand, per-
forming further immunohistochemistry can lead to the
proper diagnosis.
The correct diagnosis may prevent inappropriate
breast surgery in an individual with breast metastases
from a primary tumour elsewhere.
Case illustration 4 in the following chapter represents
a lung cancer metastasising into the breast, mimicking
pleomorphic lobular carcinoma.
The continued follow up and assessment of individ-
uals with invasive lobular carcinoma has many prob-
lems affecting the surgeon, oncologist, radiologist and
pathologist. It is essential that all members of the team
are aware of the initial diagnosis and the problems in-
volved in their specialty. They must also communi-
cate the history to any members of the team who may
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not be aware of the initial diagnosis. This will ensure
the highest level of patient management and help avoid
diagnostic error.
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